Shares of Septerna, Inc. (NASDAQ:SEPN - Get Free Report) reached a new 52-week low during trading on Tuesday . The stock traded as low as $15.83 and last traded at $16.16, with a volume of 177094 shares traded. The stock had previously closed at $18.48.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on SEPN. TD Cowen assumed coverage on Septerna in a research note on Tuesday, November 19th. They set a "buy" rating on the stock. Wells Fargo & Company started coverage on Septerna in a report on Tuesday, November 19th. They issued an "overweight" rating and a $43.00 price target for the company. Cantor Fitzgerald initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They set an "overweight" rating and a $50.00 price objective on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of Septerna in a research note on Tuesday, November 19th. They set an "overweight" rating and a $38.00 price target on the stock.
Read Our Latest Stock Report on Septerna
Septerna Trading Down 4.2 %
The business has a 50-day simple moving average of $21.80.
Institutional Investors Weigh In On Septerna
A hedge fund recently bought a new stake in Septerna stock. Rhumbline Advisers acquired a new stake in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 19,995 shares of the company's stock, valued at approximately $458,000.
Septerna Company Profile
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Read More
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
